Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin
This article was originally published in The Pink Sheet Daily
Executive Summary
Full details on the pivotal RISE and RIDE trials in diabetic macular edema at ADA meeting show that the drug improves vision and halts disease progression, paving way for FDA filing this fall.